Published in Blood Weekly, March 3rd, 2005
This IND relates to the commencement of the company's first autologous (self-derived) bone marrow transplant (BMT) trial (NIM-LETR-02) in the U.S.A. with the company's partner, TAP Pharmaceutical Products Inc. (TAP).
As previously reported, Dr. Richard Champlin, at M.D. Anderson Cancer Center in Houston, Texas, U.S.A., will be the principal investigator on this trial. A consortium of other leading clinicians and pre-eminent...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.